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ORIGINAL ARTICLEOral azithromycin given during labour decreases bacterial carriage in the
mothers and their offspring: a double-blind randomized trialA. Roca1,2, C. Oluwalana1, A. Bojang1, B. Camara1, B. Kampmann1, R. Bailey2, A. Demba3, C. Bottomley2 and U. D’Alessandro1,2,4
1) Medical Research Council Unit The Gambia, 2) London School of Hygiene and Tropical Medicine, London, UK, 3) Ministry of Health and Social Welfare,
Gambia and 4) Institute of Tropical Medicine, Antwerp, BelgiumAbstractBacterial sepsis remains a leading cause of death among neonates with Staphylococcus aureus, group B streptococcus (GBS) and Streptococcus
pneumoniae identiﬁed as the most common causative pathogens in Africa. Asymptomatic bacterial colonization is an intermediate step
towards sepsis. We conducted a phase III, double-blind, placebo-controlled randomized trial to determine the impact of giving one oral
dose of azithromycin to Gambian women in labour on the nasopharyngeal carriage of S. aureus, GBS or S. pneumoniae in the newborn at
day 6 postpartum. Study participants were recruited in a health facility in western Gambia. They were followed for 8 weeks and samples
were collected during the ﬁrst 4 weeks. Between April 2013 and April 2014 we recruited 829 women who delivered 843 babies,
including 13 stillbirths. Sixteen babies died during the follow-up period. No maternal deaths were observed. No serious adverse events
related to the intervention were reported. According to the intent-to-treat analysis, prevalence of nasopharyngeal carriage of the bacteria
of interest in the newborns at day 6 was lower in the intervention arm (28.3% versus 65.1% prevalence ratio 0.43; 95% CI 0.36–0.52, p
<0.001). At the same time-point, prevalence of any bacteria in the mother was also lower in the azithromycin group (nasopharynx, 9.3%
versus 40.0%, p <0.001; breast milk, 7.9% versus 21.6%, p <0.001; and the vaginal tract, 13.2% versus 24.2%, p <0.001). Differences
between arms lasted for at least 4 weeks. Oral azithromycin given to women in labour decreased the carriage of bacteria of interest in
mothers and newborns and may lower the risk of neonatal sepsis.
Trial registration ClinicalTrials.gov Identiﬁer NCT01800942.
© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open
access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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E-mail: aroca@mrc.gmBackgroundThere are more than 4 million neonatal deaths annually and a
third are caused by severe bacterial disease, which mainly
presents as sepsis [1]. In sub-Saharan Africa, the limited avail-
able data show that neonatal sepsis is caused by both Gram-© 2016 The Authors. Published by El
This is an opositive and Gram-negative bacteria [2–4], although more
than half of the cases are attributable to the former, particularly
Staphylococcus aureus [1], Streptococcus pneumoniae and group B
streptococcus (GBS) [3].
Early-neonatal sepsis is mainly due to intrapartum bacterial
vertical transmission [2] during delivery (in the birth canal) or
during the ﬁrst weeks of life as a result of the close physical
contact with the mother if she carries pathogenic bacteria
[1,5–7]. If newborns are mainly infected by their mother, an
intervention that is able to reduce maternal bacterial carriage
should prevent vertical transmission and consequently neonatal
sepsis.Clin Microbiol Infect 2016; 22: 565.e1–565.e9
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565.e2 Clinical Microbiology and Infection, Volume 22 Number 6, June 2016 CMIAzithromycin is a macrolide with a wide antimicrobial
spectrum [8] currently licensed for use in children >6 months
of age for a wide range of infections [9,10]. As part of the
WHO-recommended trachoma control strategy, mass azi-
thromycin treatment campaigns in countries where trachoma is
endemic [11–13] decreased both the nasopharyngeal pneu-
mococcal carriage [14] and the overall childhood mortality [15].
Azithromycin has also been used in pregnant women in sub-
Saharan Africa in several trials designed to reduce the incidence
of maternal malaria and preterm deliveries and low-birthweight,
but a meta-analysis found no effect of these outcomes [16].
However, a recent study conducted in Papua New Guinea
showed 25% reduction of low-birthweight infants after
including monthly azithromycin (4 g) for 3 months to the
standard sulphadoxine-pyrimethamine during the last months of
pregnancy [17]. Blocking vertical transmission has already been
used successfully in the context of GBS, the main bacterium
causing neonatal sepsis in developed countries, in Europe [18]
and USA [19]. But whereas in Europe and the USA treatment
is targeted at women with GBS vaginal carriage, in sub-Saharan
Africa systematic treatment may be more feasible, since half of
pregnant women are carriers of bacteria associated with
neonatal sepsis in the region [20]. In a ﬁrst proof-of-concept
assessing the potential of a new intervention to prevent
neonatal sepsis, we evaluated the efﬁcacy of one oral dose of
azithromycin administered to women in labour in decreasing
bacterial carriage (S. aureus, GBS and S. pneumoniae) both in the
mother and her newborn.
Methods/Design
The study protocol has been published elsewhere [21]. Brieﬂy,
this was a phase III, double-blind, placebo-controlled, random-
ized trial in which women in labour were randomized to
receive a single dose of oral azithromycin (2 g) or placebo.
The packaging and labelling of the interventional medical
product was conducted by IDIFARMA. Azithromycin and
placebo were provided as tablets packed in blisters. IDI-
FARMA created the randomization list (permuted blocks) and
numbered the blisters according to the list. One blister pack
of interventional medical product contained four tablets each
of 0.5 g of azithromycin or placebo (2 g). The active drug and
the placebo looked identical. The statistician of the Data
Safety Monitor Board (DSMB) kept the list until the ﬁnal
database was locked. The investigators were blinded to the
patient’s allocation until the database was locked, when the
code was broken.
The study was based at the Jammeh Foundation for Peace
(JFP), a government-run health centre located in western
Gambia that manages 4500 deliveries/year. The population in
the catchment area is representative of The Gambia and it© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microb
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4covers the main ethnic groups. Approximately 70% of deliveries
in the country occur in health facilities (Jasseh et al. personal
communication). The climate of the area is typical of the sub-
Sahel region. Illiteracy is high [22].
Between April 2013 and April 2014, women in labour aged
18–45 years were recruited when attending the JFP labour
ward. They had signed consent to participate in the study
during their antenatal visits. Eligibility was re-assessed in the JFP
labour ward based on the exclusion criteria: (i) known human
immunodeﬁciency virus infection; (ii) any acute or chronic
condition that could interfere with the study as judged by the
research clinicians; (iii) planned travel out of the catchment
during the follow up; (iv) known risk of caesarean section; (v)
likely referral during labour (eclampsia or severe anaemia); (vi)
known multiple pregnancy; (vii) known severe congenital mal-
formation or intrauterine death conﬁrmed before randomiza-
tion; (ix) known allergy to macrolides; (x) consumption of
antibiotic within the previous week.
Pre-intervention samples were collected during labour
(nasopharyngeal swab (NPS) and vaginal swab (VS)). An NPS
was collected from the baby within 6 h after birth. After
discharge, mothers and babies were visited at home for
2 months, daily during the ﬁrst week and weekly thereafter.
NPS and breast milk samples were collected at days 3, 6, 14 and
28. In addition, a VS was collected between days 8 and 10 after
delivery at the postnatal check visit at JFP.
The primary end point was prevalence of carriage of
S. aureus, GBS or S. pneumoniae in the NPS sample of the
newborn at day 6. Secondary end points included: (i) bacterial
carriage in the NPS of the baby and the mother; (ii) carriage in
the VS and breast milk during the ﬁrst 4 weeks after delivery;
and (iii) prevalence of carriage of any of the study bacteria non-
susceptible to azithromycin.
To evaluate the safety of the intervention on mothers and
newborns, adverse events were monitored and assessed
throughout the follow up. Diagnoses were based on clinical
judgement according to the study clinicians.
A local safety monitor (LSM) and a DSMB reviewed serious
adverse events during the trial, and the trial was monitored by
an independent clinical trials monitor. The study was approved
by the joint Gambia Government/Medical Research Council
(MRC)/Ethics Committee.
Sample collection and laboratory analysis
The NPS, low VS and breast milk samples were collected as
part of the trial; see details elsewhere [24].
Laboratory procedures
Samples were processed following standard microbiological
procedures [21].iology and Infectious Diseases, CMI, 22, 565.e1–565.e9
.0/).
TABLE 1. Baseline characteristics of study participants
Azithromycin Placebo
Mothers’ characteristics (n [ 414) (n [ 415)
Age, median (interquartile range) 26.0 (22.0–30.0) 25.0 (22.0–30.0)
Ethnicity, n (%)
Madinka 161 (40.1) 187 (45.8)
Fula 77 (19.2) 64 (15.7)
Jola 68 (17.0) 56 (13.7)
Other 95 (23.7) 101 (24.8)
Season of delivery, n (%)a 141 (34.1) 143 (34.5)
Mode of delivery, n (%)
Vaginal 404 (97.6) 410 (98.8)
Caesarean 10 (2.4) 5 (1.2)
Multiple pregnancy, n (%) 5 (1.2) 9 (2.2)
Hours from treatment to delivery,
median (interquartile range)
3.2 (1.1,8.3) 2.9 (1.3,6.3)
Hours from rupture of membrane to
delivery, median (interquartile range)b
0.4 (0.1,1.8) 0.3 (0.1,1.3)
Newborn’s characteristics (n [ 419) (n [ 424)
Gender, females n (%) 207 (49.4) 198 (46.7)
Apgar score at birth, n (%)
0 6 (1.4) 6 (1.4)
1–6 8 (1.9) 5 (1.2)
7–10 402 (96.6) 408 (97.4)
Weight, n (%)c 3.1 (2.8–3.5) 3.1 (2.9–3.4)
Gestational age (weeks), n (%)d 36.0 (35.0–38.0) 36.0 (35.0–38.0)
aRainy season: children born June to October.
bTime of rupture of membranes is missing in n = 441 (230 in the azithromycin and
211 in the placebo arm).
cWeight missing in n = 2 (both in the placebo arm).
dGestational age missing in n = 33 (16 in the azithromycin and 17 in the placebo
arm).
CMI Roca et al. Azithromycin in labour lowers carriage in newborns 565.e3Sample size rationale
The sample size was chosen to provide 88% power to detect a
20% reduction in the primary end point (i.e. from 60% [23] to
48%). We assumed that NPS would not be available for 15% of
newborns at day 6.
Data management and statistical analysis
Case-report-forms and laboratory forms were reviewed before
being double entered into OpenClinica (www.openclinica.com).
The analysis was carried out using STATA (version 13.1). We
compared the prevalence of bacterial carriage in mothers and
newborns allocated to the azithromycin and placebo groups
(i.e. intent-to-treat analysis). Additional analyses included car-
riage acquisition rates for the periods 0–6 days and 7–28 days.
Ratios and 95% CI were calculated for each comparison, and
Fisher’s exact test was used to compute p values. We included
twins, but did not adjust the 95% CI and signiﬁcance tests for
the effect of clustering because the design effect was negligible.
A Poisson regression model was used to assess the effect of
the intervention on prevalence of bacterial carriage across all
time-points. The model included the baseline carriage status of
the mother and time as covariates, and robust standard errors
were used to account for the dependence between observa-
tions from the same individual as well as the model mis-
speciﬁcation (carriage status does not follow a Poisson
distribution).
For the primary end point, three additional analyses were
performed: (i) a sub-group analysis in women who delivered
2 hours or more after taking the drug; (ii) a sensitivity analysis
using multiple imputation in which bacterial carriage was
imputed from baseline demographic data (age and ethnicity for
mothers, and sex and birthweight for newborns) and from
carriage data at other time-points; and (iii) a per protocol
analysis.ResultsStudy population
In all, 1061 women in labour were assessed for eligibility and
829 (78.1%) were recruited, randomized and treated (414
azithromycin and 415 placebo) (see Table 1).
These 829 recruited women delivered 843 babies (Fig. 1).
Seven neonatal deaths (4.7%) had a clinical diagnosis of sepsis,
meningitis or pneumonia according to the adverse events form;
four in the placebo group (none with underlying conditions),
and three in the azithromycin group (all with underlying con-
ditions—one each of congenital heart disease, suspicion of
vitamin K deﬁciency with haemorrhagic disease, and aspiration
of gastric content). There were no maternal deaths reported.© 2016 The Authors. Published by Elsevier Ltd on behalf of Eu
This is an oOf the 25 maternal hospitalizations, 18 (72%) were due to la-
bour complications and three had diagnosis of puerperal sepsis
(one in the azithromycin group and two in the placebo group).
No adverse events/serious adverse events related to the
intervention were reported for the newborns. One mother
developed moderate urticarial rash that lasted for 3 days.
Prevalence of carriage
At day 6, samples were collected from 93% of the newborns
that were alive and at all other times at least 90% of mothers
and newborns provided samples (Table 2, Fig. 2).
Pre-intervention samples. Prevalence of carriage in VS and NPS
was similar between study arms for all bacteria.
Post-intervention NPS. All study bacteria were less common in
newborns in the azithromycin group than in the placebo group.
At day 6, the prevalence of nasopharyngeal carriage of study
bacteria in newborns was 28.3% in the azithromycin group
versus 65.1% in the placebo group (prevalence ratio
(PR) = 0.43; p <0.001). Similarly, in mothers bacterial carriage
was lower in the azithromycin group, with PR ranging from 0.08
(for S. pneumoniae at day 6) to 0.57 (for S. aureus at day 28).
Post-intervention breast milk samples. The prevalence of car-
riage of study bacteria in breast milk was signiﬁcantly lower
among mothers from the azithromycin group at day 6 (9.6%
versus 21.9%; PR = 0.44; p <0.004).
Post-intervention VS. The prevalence of carriage of study
bacteria in the VS collected post-intervention was lower in the
azithromycin group than in the placebo group (13.2% versusropean Society of Clinical Microbiology and Infectious Diseases, CMI, 22, 565.e1–565.e9
pen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Randomised (n=829)
Assessed for eligibility 
(n=1061)
Excluded (n=232)
- Arrived late (n=128)
-Took anƟbioƟcs (n=47)
-Other reasons (n=57)
Allocated  Plcbo (m=415, brth=424)
Withdrawals (n=0)
Deaths (n=4)
Day 0  (m=415 nb=418)
NPSm=415 NPSc=416  VS=415 
Day 6  (m=413 nb=411)
NPSm=397 NPSc=387 BM=397 
Day 3  (m=415 nb=414)
NPSm=402 NPSc=396 BM=399 
Day 8–10  (m=412 nb=409)
VS=397
Day 14  (m=408 nb=405)
NPSm=390 NPSc=381 BM=387 
Day 28 (m=407 nb=404)
NPSm=386 NPSc=374 BM=384 
Day 56 (m=398 nb=393)
Withdrawals (n=2)
Deaths (n=1)
Withdrawals (n=1)
Deaths (n=1)
Withdrawals (n=4)
Deaths (n=0)
Withdrawals (n=1)
Deaths (n=0)
Withdrawals (n=9)
Deaths (n=2)
Allocated  Azithro (m=414  brth=419)
Withdrawals (n=1)
Deaths (n=3)
Day 0  (m=414 nb=412)
NPSm=414 NPSc=407 VS=414 
Day 6  (m=412 nb=406)
NPSm=395 NPSc=378 BM=395 
Day 3  (m=413 nb=408)
NPSm=400 NPSc=386 BM=394 
Day 8–10  (m=410 nb=402)
VS=393
Day 14  (m=409 nb=401)
NPSm=390 NPSc=372 BM=388 
Day 28 (m=400 nb=391)
NPSm=381 NPSc=359 BM=381 
Day 56 (m=393 nb=383)
Withdrawals (n=1)
Deaths (n=1)
Withdrawals (n=2)
Deaths (n=2)
Withdrawals (n=1)
Deaths (n=0)
Withdrawals (n=9)
Deaths (n=1)
Withdrawals (n=7)
Deaths (n=1)
SƟllbirths (n=6) SƟllbirths (n=7)
FIG. 1. Trial proﬁle. Abbreviations: nb, Newborns; m, Mothers; NPSn, nasopharyngeal swabs collected from newborns; NPSm, nasopharyngeal swabs
collected from mothers; BM, breast milk samples collected; VS, vaginal swabs collected. Some participants were still present until follow up but their
samples were missed in some of the visits.
565.e4 Clinical Microbiology and Infection, Volume 22 Number 6, June 2016 CMI24.2%; PR = 0.55; p <0.001). S. pneumoniae was not isolated
from VS.
Antibiotic resistance. Isolates resistant to azithromycin,
particularly S. aureus, were more common in the intervention
group for all sample types (Table 3).
Sensitivity analyses. Differences in bacterial carriage between
trial arms in the analysis stratiﬁed by time of treatment (see
Supplementary material, Table S1), the per protocol analysis
(see Supplementary material, Table S2) and the analysis of
carriage acquisition (see Supplementary material, Table S3)
were similar to those observed in the primary analysis. For
mothers recruited <2 h before delivery, prevalence of naso-
pharyngeal carriage of study bacteria at day 6 in their newborns
was 35.5% if they received azithromycin and 67.5% if they
received placebo (PR = 0.53; p <0.001).
Use of antibiotic during the follow-up period
The intervention reduced antibiotic prescription in the study
women by 40% (6.0% versus 10.1% for any antibiotic,
PR = 0.58, 95% CI 0.36–0.94; p = 0.031), but not in the© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microb
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4newborns (10.0% versus 10.1% in the azithromycin and placebo
groups, respectively; p 1.000).DiscussionOne oral dose (2 g) of azithromycin given to women in labour
substantially reduced the prevalence of S. aureus, GBS and
S. pneumoniae carriage both in the newborn and the mother.
The difference between arms was already evident at birth
(before breast feeding), probably as a result of the clearance of
bacterial pathogens from the birth canal, and was maintained
during the entire neonatal period. The prolonged effect of
azithromycin on neonatal bacterial carriage is probably attrib-
utable to its substantial effects on carriage in the mother’s
nasopharynx and breast milk and the presence of azithromycin
in the breast milk [24].
Several studies, including one in The Gambia [14], have
shown that azithromycin can reduce nasopharyngeal carriageiology and Infectious Diseases, CMI, 22, 565.e1–565.e9
.0/).
TABLE 2. Bacterial carriage in newborns and mothers Intent-to-treat analysis; nasopharyngeal swab and breast milk samples
Day 0a Day 3 Day 6b Day 14 Day 28
P’bo (%) AZI (%) PR (95% CI) p value P’bo (%) AZI (%) PR (95% CI) p value P’bo (%) AZI (%) PR (95% CI) p value P’bo (%) AZI (%) PR (95% CI) p value P’bo (%) AZI (%) PR (95% CI) p value
NPS newborn n = 416 n = 417 n = 396 n = 386 n = 387 n = 378 n = 381 n = 372 n = 374 n = 359
GBS 1.7 0.7 0.44 (0.11–1.68) 0.341 10.4 0.8 0.08 (0.02–0.24) <0.001 5.4 1.1 0.20 (0.07–0.56) 0.001 4.7 0.8 0.17 (0.05–0.57) 0.001 3.2 0.6 0.17 (0.04–0.77) 0.012
Streptococcus
pneumoniae
0.2 0.2 1.02 (0.06–16.3) 1.000 1.3 0.8 0.62 (0.15–2.56) 0.725 4.1 0.8 0.19 (0.06–0.65) 0.004 19.7 8.1 0.41 (0.28–0.61) <0.001 37.2 24.8 0.67 (0.53–0.83) <0.001
Staphylococcus
aureus
3.6 1.5 0.41 (0.16–1.04) 0.075 57.6 25.4 0.44 (0.36–0.53) <0.001 63.3 27.5 0.43 (0.36–0.52) <0.001 44.1 23.1 0.52 (0.42–0.65) <0.001 35.3 25.6 0.73 (0.58–0.91) 0.005
Any bacteria 5.5 2.2 0.40 (0.19–0.85) 0.018 62.1 26.2 0.42 (0.35–0.51) <0.001 65.1 28.3 0.43 (0.36–0.52) <0.001 57.7 29.6 0.51 (0.43–0.61) <0.001 60.4 45.7 0.76 (0.66–0.87) <0.001
NPS mother n = 415 n = 414 n = 402 n = 400 n = 397 n = 395 n = 390 n = 390 n = 386 n = 381
GBS 0.5 0.7 1.50 (0.25–8.95) 0.686 0.2 0 NA NA 0 0 NA NA 0 0 NA NA 0.5 0.3 0.51 (0.05–5.56) 1
S. pneumoniae 17.1 15.9 0.93 (0.69–1.27) 0.709 17.9 1.0 0.06 (0.02–1.15) <0.001 16.1 1.3 0.08 (0.03–0.19) <0.001 22.3 3.1 0.14 (0.08–0.25) <0.001 23.8 4.2 0.18 (0.11–0.29) <0.001
S. aureus 19.3 18.6 0.96 (0.73–1.28) 0.859 25.4 8.3 0.33 (0.23–0.47) <0.001 27.2 7.8 0.29 (0.20–0.42) <0.001 26.2 10.5 0.40 (0.29–0.56) <0.001 26.9 15.2 0.57 (0.42–0.75) <0.001
Any bacteria 34.5 32.6 0.95 (0.78–1.15) 0.607 40.0 9.3 0.23 (0.17–0.32) <0.001 40.3 9.1 0.23 (0.16–0.32) <0.001 43.8 12.8 0.29 (0.22–0.39) <0.001 45.6 19.4 0.43 (0.34–0.54) <0.001
Breast milk n = 0 n = 0 n = 399 n = 394 n = 397 n = 385 n = 387 n = 388 n = 384 n = 381
GBS — — — — 6.8 0.8 0.11 (0.33–0.37) <0.001 7.6 1.8 0.23 (0.10–0.53) <0.001 6.5 0.8 0.12 (0.04–0.39) <0.001 1.6 0.0 NA 0.031
S. pneumoniae — — — — 0.5 0 NA NA 0 0 NA NA 0.8 0.0 NA 0.124 0.0 0.0 NA NA
S. aureus — — — — 15.5 7.1 0.46 (0.30–0.70) <0.001 16.4 8.1 0.49 (0.33–0.74) <0.001 12.4 8.0 0.64 (0.42–0.99) 0.044 10.4 5.0 0.48 (0.28–0.81) 0.006
Any bacteria — — — — 21.6 7.9 0.37 (0.25–0.54) <0.001 21.9 9.6 0.44 (0.31–0.63) <0.001 17.3 8.8 0.51 (0.33–0.75) <0.001 11.7 5.0 0.43 (0.25–0.71) 0.001
Vaginal swabs n = 415 n = 414 n = 0 n = 0 n = 396 n = 386 n = 0 n = 0 n = 0 n = 0
GBS 15.9 18.1 1.14 (0.84–1.54) 0.407 — — — — 13.6 4.6 0.4 (0.20–0.56) <0.001 — — — — — — — —
S. pneumoniae 0 0 NA NA — — — — 0 0 NA NA — — — — — — — —
S. aureus 16.6 12.3 0.74 (0.53–1.04) 0.093 — — — — 14.1 8.9 0.63 (0.42–0.94) 0.026 — — — — — — — —
Any bacteria 28.9 25.1 0.87 (0.69–1.09) 0.241 — — — — 24.2 13.2 0.55 (0.40–0.74) <0.001 — — — — — — — —
Abbreviations: AZI, azithromycin; GBS, group B streptococci; NPS, nasopharyngeal swab; P’bo– placebo; PR, Prevalence Ratio.
aAt day 0, nasopharyngeal and vaginal swabs in mothers were collected before the intervention and nasopharyngeal swabs in newborns after the intervention.
bVaginal swabs were collected at day 8–10 instead.
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FIG. 2. Bacterial carriage of Staphylococcus aureus, group B streptococci (GBS) and Streptococcus pneumoniae in the different study time points for the
azithromycin (AZI) and placebo groups. (a) Newborn nasopharyngeal swabs (NPS); (b) Maternal NPS; (c) Breast milk sample.
565.e6 Clinical Microbiology and Infection, Volume 22 Number 6, June 2016 CMIof S. pneumoniae when given as prophylaxis but no studies
have investigated whether azithromycin has an effect on GBS,
and few have investigated whether it has an effect on S. aureus,
both leading causes of neonatal sepsis in sub-Saharan Africa
[3,4] and the latter the bacterium most commonly isolated
from the nasopharynx in newborns [23]. A recent study© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microb
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4comparing the impact of sulfadoxine-pyrimethamine in com-
bination with three courses of 4 g of azithromycin versus
sulfadoxine-pyrimethamine with chloroquine given monthly
during pregnancy found no difference between groups on the
prevalence of S. aureus in the maternal nasopharynx at de-
livery [25].iology and Infectious Diseases, CMI, 22, 565.e1–565.e9
.0/).
TABLE 3. Prevalence of isolates resistant to azithromycin in newborns and mothers in the different study samples
Day 0a Day 3 Day 6b Day 14 Day 28
P’bo (%) AZI (%) PR (95% CI) p value P’bo (%) AZI (%) PR (95% CI) p value P’bo (%) AZI (%) PR (95% CI) p value P’bo (%) AZI (%) PR (95% CI) p value P’bo (%) AZI (%) PR (95% CI) p value
NPS newborn n = 416 n = 417 n = 396 n = 386 n = 387 n = 378 n = 381 n = 372 n = 374 n = 359
GBS 0 0 NA NA 0.5 0 NA NA 0.5 0.3 0.51 (0.05–5.62) 1 0.3 0.3 1.02 (0.06–16.31) 1 0.0 0.3 NA NA
Streptococcus
pneumoniae
0 0 NA NA 0 0 NA NA 0.5 0 NA 0.499 1.0 0.5 0.51 (0.009–2.78) 0.686 2.1 2.2 1.04 (0.40–2.75) 1
Staphylococcus
aureus
1.0 0.7 0.77 (0.17–3.40) 1 6.8 10.6 1.56 (0.98–2.48) 0.075 5.2 12.7 2.46 (1.49–4.06) <0.001 3.4 15.3 4.49 (2.50–8.06) <0.001 4.5 16.7 3.68 (2.19–6.18) <0.001
Any bacteria 1.0 0.7 0.77 (0.17–3.40) 1 7.3 10.6 1.45 (0.92–2.28) 0.132 6.2 13.0 2.09 (1.31–3.34) 0.002 4.5 16.1 3.61 (2.15–6.08) <0.001 6.7 19.2 2.88 (1.86–4.44) <0.001
NPS mother n = 415 n = 414 n = 402 n = 400 n = 397 n = 395 n = 390 n = 390 n = 386 n = 381
GBS 0 0 NA NA 0 0 NA NA 0 0 NA NA 0 0 NA NA 0..3 0.3 1.01 (0.06–16.1) 1
S. pneumoniae 0 1.4 NA NA 0.5 0.8 1.51 (0.25–8.97) 0.686 1.0 0.8 0.75 (0.17–3.35) 1 0.8 1.8 2.33 (0.61–8.96) 0.341 0.3 1.8 7.09 (0.88–57.4) 0.037
S. aureus 2.7 1.4 0.55 (0.20–1.46) 0.327 1.7 4.0 2.30 (0.96–8.97) 0.686 3.5 5.6 1.58 (0.82–3.04) 0.177 3.1 9.2 3.00 (1.85–5.68) <0.001 2.8 12.6 4.42 (2.33–8.38) <0.001
Any bacteria 2.7 2.9 1.09 (0.49–2.45) 0.836 2.2 4.8 2.12 (0.97–4.63) 0.057 4.3 6.3 1.48 (0.81–2.69) 0.209 3.8 10.5 2.73 (1.54–4.86) <0.001 3.4 14.7 4.36 (2.43–7.85) <0.001
Breast milk n = 0 n = 0 n = 399 n = 394 n = 397 n = 385 n = 387 n = 388 n = 384 n = 381
GBS — — — — 0.5 0.3 0.51 (0.05–5.56) 1 0.5 0.3 0.50 (0.05–5.52) 1 0.3 0.3 1.00 (0.006–15.9) 1 0 0 NA NA
S. pneumoniae — — — — 0 0 NA NA 0 0 NA NA 0 0.0 NA NA 0 0 NA NA
S. aureus — — — — 1.8 4.8 2.75 (1.17–6.47) 0.017 2.0 5.1 2.51 (1.12–5.64) 0.021 0.8 5.7 7.31 (2.21–24.2) <0.001 1.3 3.7 2.82 (1.03–7.76) 0.038
Any bacteria — — — — 2.3 5.1 2.25 (1.04–4.88) 0.038 2.5 5.3 2.11 (1.01–4.42) 0.045 1.0 5.9 5.74 (2.00–16.4) <0.001 1.3 3.7 2.82 (1.03–7.76) 0.038
Vaginal swabs n = 415 n = 414 n = 0 n = 0 n = 396 n = 386 n = 0 n = 0 n = 0 n = 0
GBS 0.5 0.2 0.50 (0.05–5.51) 1 — — — — 0.3 1.5 6.06 (0.73–50.1) 0.068 — — — — — — — —
S. pneumoniae 0 0 NA NA — — — — 0 0 NA NA — — — — — — — —
S.aureus 1.7 0 NA NA — — — — 1.0 6.9 6.82 (2.41–19.3) <0.001 — — — — — — — —
Any bacteria 2.2 0.2 0.11 (0.01–0.88) 0.021 — — — — 1.3 8.4 6.67 (2.63–16.9) <0.001 — — — — — — — —
Abbreviations: AZI, azithromycin; GBS, group B streptococci; NPS, nasopharyngeal swab; P’bo– placebo; PR, Prevalence Ratio.
Azithromycin resistance was determined by E-test following the CLSI 2014 guidelines for the performance of test and interpretation of results:
(i) S. aureus isolates with E-test values 8 μg/mL
(ii) S. pneumoniae/GBS isolates with E-test values 2 μg/mL.l
aAt day 0, nasopharyngeal and vaginal swabs in mothers were collected before the intervention and nasopharyngeal swabs in newborns after the intervention.
bVaginal swab was collected at day 8–10 instead.
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565.e8 Clinical Microbiology and Infection, Volume 22 Number 6, June 2016 CMIGroup B streptococci were almost eliminated in mothers
treated with azithromycin and the prevalence was very low in
their offspring. This may have implications beyond sub-Saharan
Africa as GBS is a common cause of early neonatal sepsis in
Europe and the USA where pregnant women are screened for
GBS and, if positive, are treated during delivery with intra-
venous antibiotic [18,26]. Intravenous prophylactic treatment
with penicillin is only recommended if the women attend the
maternal ward at an early stage of labour [18]. Our data show
that azithromycin can prevent vertical transmission of GBS
and the other study bacteria even when taken <2 h before
delivery.
The prevalence of azithromycin resistance among bacterial
isolates in the intervention arm was high, particularly for
S. aureus. Although this may be worrying, such resistance is
unlikely to be sustained as resistance falls in the absence of
antibiotic pressure because of the associated ﬁtness cost [27].
In The Gambia, after mass campaigns of azithromycin treat-
ment, S. pneumoniae macrolide resistance returned to baseline
levels within 6 months [14]. Still, the selection of resistance
after azithromycin treatment should be closely monitored in
future studies because if larger studies show an effect on severe
clinical outcomes, the intervention proposed would lead to
continuous and sustained antimicrobial pressure. The impor-
tance in clinical care of such resistance is limited considering
that azithromycin is currently not used for clinical care in The
Gambia. Furthermore, as we found that the intervention
reduced antibiotic use in mothers by >40% during the follow-up
period, future larger studies should also monitor any effect on
the intervention in reducing resistance to common antibiotics.
The trial was designed as a proof-of-concept, to assess
whether azithromycin can reduce bacterial carriage in the
mother and in her offspring. It was not powered to assess the
intervention’s effect on neonatal morbidity or mortality, neither
did it attempt to standardize clinical end points. The diagnosis of
neonatal sepsis was made on a clinical basis and supported by
chest X-rays or laboratory results at admission.
Compared with the general population, study participants
beneﬁted from better care, which probably decreased
morbidity and mortality in both arms. If a study nurse suspected
an infection during a home visit, the participant was immediately
referred to the study clinicians who managed them accordingly.
Such close follow up may have increased the probability of
hospitalization in children with mild signs/symptoms of disease
who, in a real-life situation, would not have been taken to a
health facility, and this may have contributed to decreasing the
possible difference between arms. Although both arms had a
comparable number of deaths due to severe infections (sepsis,
pneumonia and meningitis), deaths in the intervention arm,© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microb
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4unlike the placebo arm, occurred in newborns with an under-
lying severe condition.
Azithromycin treatment during labour can signiﬁcantly
reduce bacterial carriage among newborns and may therefore
lower their risk of neonatal sepsis, pneumonia and meningitis.
This simple intervention could therefore have a dramatic
impact on neonatal mortality, and might also prevent puerperal
sepsis and maternal deaths. A larger randomized controlled
clinical trial is urgently needed to determine whether the
intervention is effective against these clinical outcomes. Such a
trial should also monitor the effect of the intervention on the
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